Investors expect Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)’s quarterly earnings on March, 15., as reported by Faxor. Analysts expect change of 3.85 % or $0.01 from previous year’s $-0.26 EPS compared to current’s $-0.25 EPS. Wall Street now sees -21.88 % EPS growth despite Checkpoint Therapeutics, Inc. previous quarter’s EPS of $-0.32. Ticker’s shares touched $2.9063 during the last trading session after 1.98% change.Checkpoint Therapeutics, Inc. has volume of 12,705 shares. Since February 28, 2018 CKPT has declined 53.36% and is downtrending. The stock underperformed the S&P500 by 53.36%.

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers.The company has $98.95 million market cap. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer ; and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC.Last it reported negative earnings. The Company’s pipeline consists of glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX.

For more Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) news brought out briefly go to: Globenewswire.com, Globenewswire.com, Globenewswire.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101 – GlobeNewswire” brought out on September 25, 2018, “Checkpoint Therapeutics Appoints Christian Béchon to its Board of Directors – GlobeNewswire” on October 16, 2018, “Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference – GlobeNewswire” with a publish date: August 30, 2018, “Adial Pharmaceuticals and Tonix Pharmaceuticals among Healthcare gainers; Restoration Robotics and Vaxart among losers – Seeking Alpha” and the last “Checkpoint Therapeutics up 22% – Seeking Alpha” with publication date: November 29, 2018.